Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net loss	$ (350,643)	$ (284,276)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	9,892	9,603
Non-cash operating lease cost	2,997	3,057
Non-cash interest expense and amortization of debt issuance costs	5,382	5,899
Payment on notes attributed to accreted interest related to the debt discounts	(22,057)	(11,791)
Acquired in-process research and development	12,271	23,608
Stock-based compensation	57,617	67,509
(Gain) loss on debt extinguishment	(27,701)	6,695
(Gain) on derivative liabilities	(5,300)	(100)
Loss (gain) on marketable investments	43,042	(17,047)
(Gain) loss on equity method investments	(3)	277
(Gain) loss on contingent consideration	(67,100)	100
Loss on impairment of intangible assets	90,780
Deferred income taxes	(682)	(1,834)
Changes in operating assets and liabilities, excluding effect of acquisitions:
Accounts receivable	(5,402)	(697)
Inventory	(4,496)	(5,427)
Accrued payroll	7,833	(4,941)
Prepaid expenses, deposits and other assets	4,654	(631)
Accounts payable	5,710	(3,549)
Accrued expenses and other liabilities	20,780	35,589
Deferred revenue	(2,544)	417
Right-of-use assets, operating leases	(549)	(32,509)
Other		364
Net cash used for operating activities	(225,519)	(209,684)
Investing activities
Proceeds from sale of marketable investment		124,113
Purchases of property and equipment	(9,133)	(6,662)
Net cash (used for) provided by investing activities	(23,484)	82,052
Financing activities
Proceeds from short-term debt, net of issuance costs	98,560	35,053
Proceeds from exercise of stock options and warrants	825	13,255
Repayments of debt and other obligations	(152,783)	(72,711)
Net cash provided by financing activities	286,638	110,475
Net change in cash, cash equivalents and restricted cash	37,635	(17,157)
Net effect of exchange rate changes on cash	(3,614)	428
Cash, cash equivalents and restricted cash at beginning of period	36,665	56,464
Cash, cash equivalents and restricted cash at end of period	70,686	39,735
Cash paid during the period for:
Interest	665	86
Income Taxes	29	1,200
Supplemental disclosures of non-cash investing and financing activities:
Changes to noncontrolling interests from increased ownership in Scilex Holding		23,963
ACEA acquisition consideration paid in equity		42,168
Virex Health acquisition consideration paid in equity	4,435
Deferred consideration for intangible asset acquisition	3,650
Other acquisitions, license agreements and investments paid in equity		13,689
Property and equipment costs incurred but not paid	753	1,162
Short-term debt		7,304
ACEA Therapeutics, Inc
Investing activities
Acquisition consideration paid in cash, net of cash acquired		(754)
Virex Health, Inc
Investing activities
Acquisition consideration paid in cash, net of cash acquired	(6,544)
Other Acquisitions and Investments
Investing activities
Acquisition consideration paid in cash, net of cash acquired	(7,807)	(34,645)
Public Offering Of Common Stock And Warrants 2019
Financing activities
Proceeds from equity offerings, net of issuance costs	$ 340,036	$ 134,878